- BLU9931
-
- $30.00 / 2mg
-
2025-09-22
- CAS:1538604-68-0
- Min. Order:
- Purity: 99.85%
- Supply Ability: 10g
- BLU 9931
-
- $1.00 / 1KG
-
2020-01-01
- CAS:1538604-68-0
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 10000KGS
|
| | BLU9931 Basic information |
| Product Name: | BLU9931 | | Synonyms: | BLU 9931;BLU9931;BLU-9931;LM-3610;LM-3610; BLU9931;2-Propenamide,N-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]-3-methylphenyl]-;BLU 9931;BLU-9931;BLU9931, 98%, a potent, selective, and irreversible FGFR4 inhibitor | | CAS: | 1538604-68-0 | | MF: | C26H22Cl2N4O3 | | MW: | 509.38 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1538604-68-0.mol |  |
| | BLU9931 Chemical Properties |
| density | 1.361±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥50.9 mg/mL in DMSO; insoluble in H2O; ≥2.53 mg/mL in EtOH with gentle warming and ultrasonic | | form | Powder | | pka | 13.15±0.70(Predicted) | | color | Off-white to light yellow |
| | BLU9931 Usage And Synthesis |
| Uses | BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity[1]. | | Definition | BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 3 nM and a Kd of 6 nM. BLU9931 has significant antitumor activity. BLU9931 makes a covalent bond with Cys552 within the ATP-binding pocket of FGFR4, which is not present in FGFR1-3. BLU9931 inhibited gastric cancer cell growth in a transplanted mouse model[1].
| | Synthesis | The general procedure for the synthesis of N-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]-3-methylphenyl]-2-acrylamide from the compound (CAS: 1538605-10-5) and acryloyl chloride was performed as follows: the N'-[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]- 6-methylbenzene-1,2-diamine (5.16 g, 11.33 mmol) was dissolved in dichloromethane (DCM, 100 mL) and cooled to 0 °C. Subsequently, N,N-diisopropylethylamine (DIEA, 1.781 mL, 10.20 mmol) and acryloyl chloride (1.013 mL, 12.47 mmol) were sequentially added at 0 °C and the reaction mixture was stirred for 2 h at this temperature. After completion of the reaction, the mixture was directly sampled onto a silica gel column and purified by fast column chromatography using 0-100% ethyl acetate (EtOAc)/hexane gradient elution. Finally, the target product N-[2-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]-3-methylphenyl]-2-propenamide was obtained as an off-white solid (3.5 g, 61% yield). The mass spectrum (electrospray positive ion mode, ES+) showed the molecular ion peak m/z 509 [M+H]+, which is consistent with the calculated value of the molecular formula C26H22Cl2N4O3.1H NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 9.23 (s, 1H), 8.68 (s, 1H), 7.82-7.65 (m, 2H) , 7.51 (s, 2H), 7.21 (m, 1H), 7.12 (d, J = 6.8 Hz, 1H), 7.01 (s, 1H), 6.49 (dd, J = 17.0, 10.2 Hz, 1H), 6.28-6.15 (m, 1H), 5.68 (dd, J = 10.2, 2.0 Hz, 1H), 3.97 (s, 6H) , 2.19 (s, 3H). | | in vivo | BLU9931 (10-100 mg/kg; oral administration; twice every day; for 21 days; mice) treatment demonstrates antitumor activity in HCC xenograft models[1]. | Animal Model: | Mice injected with Hep 3B cells[1] | | Dosage: | 10 mg/kg, 30 mg/kg or 100 mg/kg | | Administration: | Oral administration; twice every day; for 21 days | | Result: | Resulted in dose-dependent growth inhibition of Hep 3B tumors. Prevented weight loss in a dose-dependent manner.
|
| | IC 50 | FGFR1: 591 nM (IC50); FGFR2: 493 nM (IC50); FGFR3: 150 nM (IC50); FGFR4: 3 nM (IC50) | | References | [1] Norihiko Sasaki. “FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.” Cancers (2020).
|
| | BLU9931 Preparation Products And Raw materials |
|